Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (212)	5/1/1998 7:06:00 AM
From: Dr. Bob	Read Replies (1) \| Respond to of 496

To all, Just read the annual report, and I have to reiterate what a good company I think this is. 1. $8/share in cash, and lots of intellectual property, making downside pretty limited - as evidenced also by the strong support at 18. 2. Excellent business model - develop the concepts, then form partnerships, and let the partner pay for the cost of bringing the drug to market. 3. Excellent scientific staff - Dr. Snyder is truly one of the great pharmacologists of our era, and ties GLFD into the strong Hopkins program. Just in case anyone's out there lurking, and hadn't heard the strong points of GLFD listed lately! Bob